Domestic Medical Device Leader Captures 75% of Export Market, Files for IPO
BrosMed Medical
High-end Medical Device Designer, Manufacturer, and Distributor
Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later!
Market value surged nearly 30 times in three years
Another Chinese-Made Medical Device Company, Rushing for IPO!
On December 24, according to the Shenzhen Stock Exchange's official website, BrosMed Medical Co., Ltd. (referred to as "BrosMed Medical")GEM IPO Accepted for Review, the tutoring institution is CICC. According to the prospectus (draft for submission), BrosMed Medical Co., Ltd.IPO to Raise 1.7 Billion Yuan, indicating that the momentum of this listing is "fierce".
BrosMed Medical was founded in 2012 in Dongguan, Guangdong, China.Market value soared nearly 30 times within three years, currently ranked at the top of Dongguan's interventional medical device companies.
As the largest balloon catheter manufacturer in China, BrosMed MedicalAwarded the title of "Little Giant" enterprise by the Ministry of Industry and Information Technology in 2022, and recognized as a national high-tech enterprise in 2023., and has now established nearly ten subsidiaries and offices worldwide.
It is reported that BrosMed Medical initiated its IPO process on October 13, 2023, during which it completed eight phases of coaching work, with the entire process lasting over two years.
Before preparing for the IPO, the company's capital recognition spanned its entire development cycle, with a total completion of4 Rounds of Financing, including obtainingTencent Ventures, Hillhouse Capital, IDG Capital, T&W Venturewith the support of top-tier investment institutions.
Among them, it was completed in just 4 months in 2020.Hundreds of Millions of Dollars in Series C Financing, which was led byLed by Hillhouse CapitalAccording to reports, Hillhouse has successively invested inPeijia, Qiming, MicroPort Companies, and now all the companies in the series have successfully gone public.June 2025Series D FinancingIn China, top-tier institutions such as IDG Capital have jointly entered the market.
So why is BrosMed Medical so favored by capital tycoons? Does the company possess sufficient internal strength and long-term value? Let's explore.
Capture 75% of the export market
How strong is BrosMed Medical?
For investors, the present and future of enterprisesProfitabilityThis is often the core focus. For technology innovation enterprises,Self-developed Technologies and ProductsHow resilient it is determines the company's revenue and development.
It is reported that the initial team of BrosMed Medical came from Yepmed Medical, the "pioneer" of China-produced interventional devices. After 13 years of development, it has grown into...A globally renowned brand of high-quality transvascular interventional medical devices.
Currently, the company has already owned includingThree series of coronary balloon dilation catheters, six series of peripheral balloon dilation catheters, hydrophilic guidewires, arterial sheaths, and various interventional accessories are part of the product lineup.
In terms of self-developed technology, as of 2025, a cumulative total has been achieved.More than 200 patents, nearly 100 trademarks, a number of technologies fill the gap in China, and the balloon catheter products are among the world's leading categories.
Strong R&D capabilities and a rich product pipeline also provide strong momentum for its commercial development.
According to Frost & Sullivan, BrosMed Medical ranked fourth in the Chinese Coronary Balloon Dilation Catheter Market in 2024.(China's First Domestic Brand), ranking fifth in the peripheral artery balloon dilation catheter market.
Products have been sold toMore than 100 countries worldwide, the export volume of coronary balloon catheters has been consistentlyRanked First Among Chinese Brands. Outside of China, BrosMed MedicalEurope, America, JapanDeveloped countries also have a fairly good market performance.
According to the Economic Observer, in recent years, BrosMed Medical has consistently ranked at the top in the export volume of vascular interventional balloon catheters.More than 75% of the export volume of domestically produced brands; The company's total production and sales account for more than 50% of all domestically produced brands in China.
At the enterprise operation level, the performance was equally impressive. From 2022 to 2024, the company's operating revenue increased from 207 million yuan to 460 million yuan, with an average annual compound growth rate of 48.98%.In the first half of 2025, revenue reached 303 million yuanSuch a growth rate is truly remarkable in the medical device industry.
From the perspective of corporate technology products and business layout, BrosMed Medical can be described as promising for the future. This attempt to go public represents BrosMed Medical's transition from a high-growth "little giant."A Crucial Leap Towards Becoming a Platform Enterprise.
However, currentlyIntense Competition in the Vascular Intervention Sector, inHeroes CompeteAndCentralized Procurement Under the KnifeUnder the pressure, how far can BrosMed Medical go?
Thousands of Companies Compete in a Billion-Dollar Track
Can BrosMed Medical Successfully Overcome the Challenge?
In terms of market prospects, the size of China's vascular intervention market will reach approximately 62 billion yuan in 2024.It is expected to increase to RMB 105 billion by 2030.In addition, at the policy level, the "14th Five-Year Plan" has identified high-end vascular interventional devices as a key breakthrough direction.The Upward Trend of Domestic SubstitutionJust in time.
But from the perspective of industry cases, BrosMed Medical's path to going public has also been accompanied byClear Challenges。
For example,Orthopedic Leader BrosMed MedicalAfter experiencing high growth following its listing in 2017, it encountered setbacks in performance and stock price after being affected by the centralized procurement in 2021. It later achieved recovery by expanding new businesses and accelerating overseas expansion. This holds significant implications for BrosMed Medical:
Currently, more than half of the company's revenue comes from overseas, and there is still significant room for growth in the Chinese market. Meanwhile, the vascular intervention sector where BrosMed Medical is located is also..."Major 'Disaster Area' of Domestic Centralized Procurement"。
In the previous national coronary stent procurement in China, out of 26 bidding products, only 10 were selected.Average price reduction of approximately 93%, with an extreme case of a 98% price reduction.
The huge profits have been slashed, and the fluctuations in volume and price are unbearable for a large number of medical device companies.
Moreover, with the deepening of the "localization" process of foreign medical device companies and the "latecomers" of Chinese medical device companies catching up,The "Involution" of the Cardiovascular Track in ChinaHas become increasingly intense.
This time, BrosMed Medical's initial public offering (IPO) is also intended to further expand its influence in the Chinese market and balance risks. Meanwhile, the company plans to invest 450 million yuan.R&D in new fields such as neurointervention, which is precisely aimed at building diversified growth points toDiversify Risk。
So, can BrosMed Medical successfully go public this time and further expand its market in China? After the IPO, will it be able to maintain high R&D investment intensity to consolidate its technological barriers? Will its future commercialization withstand the tests of time, capital, and market? We will continue to follow up.
